

Axitinib AXIS

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Less serious adverse events observed



Other adjustments



Only improved PFS mature data shows no OS advantage and no improved QoL



Axitinib AXIS

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
 Therapeutic Indication: Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokine
 Experimental Arm: Axitinib
 Control Arm: Sorafenib



